InSphero wins CTI grant to develop 3D cardiac microtissues

It is not the first time that InSphero is supported by CTI. Previously, the CTI supported InSphero in 2009 and 2010 during the development of 3D rat-liver microtissues.  In addition the company was awarded with the CTI Start-up Label in 2010. After the succesful launch of 3D rat-liver microtissues in 2011, this new grant allows to accelerate the introduction of new microtissues to mimick cardiomyocyte, kidney and neuronal tissue. InSphero receives excellent support by the research groups of Prof. Christian Zuppinger at the University of Berne, Prof. Olivier Devuyst at the University of Zurich, and Dr. Laurent Barbe at the CSEM in Landquart to develop, characterize and apply these new products to compound testing.

"InSphero's GravityPLUS technology is very versatile to re-aggregate cells from different sources into highly functional, scaffold-free 3D microtissue spheroids. Here at the company we excel in mass producing these microtissues in a highly reproducible manner, to be shipped assay-ready to our customers. With this CTI project and the support of our partners we will be able to offer the largest product portfolio of scaffold-free 3D microtissues for toxicology and efficacy testing", says Dr. Jan Lichtenberg, CEO at InSphero AG.